Measurement strategies for indirect costs in economic evaluations

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 6, 2003, Pages 703-716

  Evans, Christopher ^a   Mertzanis, Polyxane ^a   Abetz, Linda ^a  

^a MAPI VALUES   (United States)

Author keywords

Productivity; Psychometrics; Recall; Self report; Work performance

Indexed keywords

ABSENTEEISM; ANALYTICAL ERROR; CAPITAL; CLINICAL TRIAL; COST; ECONOMIC EVALUATION; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; MEASUREMENT; PRODUCTIVITY; PSYCHOMETRY; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; VALIDATION PROCESS;

EID: 0348219033     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.6.703     Document Type: Review

References (56)

1. Liljas B. How to calculate indirect costs in economic evaluations. PharmacoEconomics 13, 1-7 (1998).
2. Crystal-Peters J, Crown W, Goetzel R et al. The cost of productivity losses associated with allergic rhinitis. Am. J. Manag. Care 6, 373-378 (2000).
3. Rothermich E, Pathak D. Productivity cost controversies in cost-effectiveness analysis: review and research agenda. Clin. Ther. 21, 255-267 (1999).
4. Weisbrod B. The valuation of human capital. J. Pol. Econ. 69, 425-436 (1961).
5. Koopmanschap M, Rutten F. The impact of indirect costs on outcomes of health care programs. Health Econ. 3, 385-393 (1994).
6. Luce B, Manning W, Siegel J, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Cost-effectiveness in Health and medicine. Gold M, Siegel J, Russell L et al (Eds). Oxford University Press, NY, USA. (1996).
7. Koopmanschap M, Rutten F. Indirect costs in economic studies: confronting the confusion. PharmacoEconomics 4, 446-454 (1993).
8. Koopmanschap M, Rutten F. A practical guide for calculating indirect costs of disease. PharmacoEconomics 10, 460-466 (1996).
9. Johannesson M, Karlsson G. The friction cost method: a comment. J. Health Econ. 16, 249-255 (1997).
10. Koopmanschap M, Rutten F, van Inevald B, van Roijen L. Reply to Johanneson's and Karlsson's comment. J. Health Econ. 16, 257-259 (1997).
11. Brouwer W, Koopmanschap M, Rutten F. Patient and informal caregiver time in cost-effectiveness analysis: a response to the recommendations of the Washington panel. Int. J. Tech. Assess. Health Care 14, 505-513 (1998).
12. Brouwer W, Koopmanschap M, Rutten F. Productivity costs measurement through quality of life? A response to the recommendations of the Washington panel. Health Econ. 6, 253-259 (1997).
13. Evans C, Crawford B. Data collection methods in prospective economic evaluations: how accurate are the results? Value Health 3, 277-286 (2000).
14. Evans C, Crawford B. Patient self reports in pharmacoeconomic studies: their use and impact on study validity. PharmacoEconomics 15, 241-256 (1999).
15. Evans C, Crawford B. Direct medical costing for economic evaluations: methodologies and impact on study validity. Drug Info. J. 34, 173-184 (2000).
16. Elixhauser A, Halpern M, Schmier J, Luce B. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med. Care 36, MS1-MS9 (1998).
17. Wimo A, Wetterholm A, Mastey V, Winblad B. Evaluation of healthcare resource utilization and caregiver time in anti-dementia drug trials - a quantitative battery. In: Health Economics of Dementia. Wimo A, Jönsson B, Karlsson G et al. (Eds). John Wiley & Sons, NY, USA (1998).
18. Thompson S, Wordsworth S. An annotated cost questionnaire for completion by patients. HERU Discussion Paper No. (03/01).
19. Scientific Advisory Committee of the Medical Outcomes Trust. Medical Outcomes Trust bulletin. 3(4), 1-4 (1995).
20. Fayers P, Machin D. Quality of Life: Assemment, Anaysis and Interpretation. John Wiley and Sons, NY, USA (2000).
21. Hays R, Anderson R, Revecki D. Psychometric Evaluation and Interpretation of Health Related Quality of Life Data. Rapid Communications of Oxford Ltd., Oxford, UK (1995).
22. Anderson RT, Aaronson NK, Bullinger M, McBee WL. a review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. PharmacoEconomics 10, 336-355 (1996).
23. Coons S, Rao S, Keininger D, Hays R. A comparative review of generic quality-of-life instruments. PharmacoEconomics 17, 13-36 (2000).
24. Pollard W, Bobbitt R, Bergner M et al. The sickness impact profile: reliability of a health status measure. Med. Care 14, 146-155 (1976).
25. McDowell J, Newell C. Measuring Health: a Guide to Rating Scales and Questionnaires. Second Edition. Oxford University Press, NY, USA (1996).
26. Jette A, Davies A, Cleary P et al. The functional status questionnaire: reliability and validity when used in primary care. J. Gen. Intern. Med. 1, 143-149 (1986).
27. Shikar R, Rentz AM, Halpern MT, Khan ZM. The health and work questionnaire (HWQ): an instrument for assessing workplace productivity in relation to worker health. Value Health 4, 181 (2001).
28. Croog S, Sudilovsky A, Levince S, Testa M. Work performance, absenteeism and antihypertensive medications. J. Hypertension. 5(Suppl. 1), S47-S54 (1987).
29. Reilly M, Zbrozek A, Dukes E. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4, 353-365 (1993).
30. Van Roijen L, Essink-Bot M, Koopmanschap M et al. Labor and health status in economic evaluation of health care: the health and labor questionnaire. Intl. J. Tech. Assess. in Health Care 12(3), 405-415 (1996).
31. Hakkaart-van Roijen L, Essink-Bot M. Manual Health and Labour Questionnaire. Rotterdam: Institute for Medical Technology Assessment. (2000).
32. Endicott J, Nee J. Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psycho. Bull. 33(1), 13-16 (1997).
33. Lerner D, Amick B, Rogers W et al. The work limitations questionnaire. Med. Care 39(1), 72-85 (2001).
34. Lerner D, Amick B, Lee J et al. Relationship of employee-reported work limitations to work productivity. Med. Care 41, 649-659 (2003).
35. Kessler R, Barber C, Beck A et al. The World Health Organization health and work performance questionnaire. J. Occupational Environ. Med. 45(2), (2003).
36. Koopman C, Pelletier KR, Murray JF et al. Stanford/American Health Association Presenteeism Scale: Linking health and productivity. J. Occupational Environ. Med. 44(1), 1-7 (2002).
37. Davies G, Santanello N, Gerth W et al. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalagia 19, 497-502 (1999).
38. Lerner D, Amick B, Malspeis S et al. The migraine work and productivity loss questionnaire: concepts and design. Qual. Life Res. 8(8), 699-710 (1999).
39. Lerner D, Amick B, Malspeis S et al. The angina-related limitations at work questionnaire. Qual. Life Res. 7, 23-32 (1998).
40. Lerner D, Amick B, Rogers W et al. The work limitations questionnaire. Med. Care 39(1), 72-85 (2001).
41. Johns G. Absentee estimates by employees and managers: divergent perspectives and self-serving perceptions. J. Applied. Psych. 79(2), 229-239 (1994).
42. Severens J, Mulder J, Laheij R, Verbeek A. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in the Netherlands. Soc. Sci. Med. 51, 2439-2249 (2000).
43. Revicki D, Irwin D, Reblando J et al. The accuracy of self-reported disability days. Med. Care 32(4), 401-404 (1994).
44. Spector P. Method variance as an artifact in self-reported affect and perceptions at work: myth or significant problem? J. Applied Psych. 72(3), 438-443 (1987).
45. Mark J. A brief history of productivity measurement. In: Handbook for Productivity Measurement and Improvement. Christopher W, Thor C (Eds). Productivity Press, OR, USA (1993).
46. Forte D. Measuring federal government productivity. In: Handbook for Productivity Measurement and Improvement. Christopher W, Thor C (Eds). Productivity Press, OR, USA (1993).
47. Soniat E, Raaum R. Government productivity measurement as an analytical tool. In: Handbook for Productivity Measurement and Improvement. Christopher W, Thor C (Eds). Productivity Press, OR, USA (1993).
48. Thomas B, Baron J. Evaluating knowledge worker productivity: literature review. USACERL Interim Report FF-94/27. US Army Construction Engineering research Laboratories. (1994).
49. Osterhaus J, Gutterman D, Plachetka J. Healthcare resource and lost labour costs of migraine headache in the US. PharmacoEconomics 2(1), 67-76 (1992).
50. Brouwer W, Koopmanschap M, Rutten F. Productivity losses without absence: measurement validation and empirical evidence. Health Policy 48, 13-27 (1999).
51. Cockburn I, Bailit H, Berndt E, Finkelstein S. Loss of work productivity due to illness and medical treatment. J. Occupational Environ. Med. 41(11), 948-953 (1999).
52. Dalton D, Mesch D. On the extent and reduction of avoidable absenteeism: an assessment of absence policy provisions. J. Applied Psych. 76(6), 810-817 (1991).
53. Von Korff M, Stewert W, Simon D et al. Migraine and reduced work performance: a population based diary study. Neurology 50, 1741-1745 (1998).
54. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. PharmacoEconomics 11 (5), 385-388 (1997).
55. Schulman E, Cady R, Henry D et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, Placebo-controlled clinical trial. Mayo Clinic Proc. 75(8), 782-789 (2000).
56. Reilly M, Tanner L, Meltzer E. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin. Drug Invest. 11(5), 278-288 (1996).